Ascendiant Capital Markets Boosts Allarity Therapeutics (NASDAQ:ALLR) Price Target to $11.00

Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) had its price objective raised by analysts at Ascendiant Capital Markets from $10.25 to $11.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock.

A number of other equities research analysts have also weighed in on the stock. Wall Street Zen raised shares of Allarity Therapeutics to a “hold” rating in a report on Saturday, May 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $11.00.

Get Allarity Therapeutics alerts:

Read Our Latest Stock Analysis on ALLR

Allarity Therapeutics Stock Down 5.1%

NASDAQ ALLR opened at $1.11 on Wednesday. Allarity Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $1.84. The business has a 50 day moving average price of $1.29 and a two-hundred day moving average price of $1.32. The stock has a market cap of $17.66 million, a PE ratio of -1.42 and a beta of 0.56.

Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. Sell-side analysts anticipate that Allarity Therapeutics will post -0.92 EPS for the current fiscal year.

Allarity Therapeutics Company Profile

(Get Free Report)

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.

See Also

• Five stocks we like better than Allarity Therapeutics
• Marex Stock Doubles on Record Profits, But Can the Rally Continue?
• 2 “Cheap for a Reason” Airline Stocks That May Be Worth the Risk
• Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
• 3 Healthcare Stocks for 3 Stages of Life

Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.